Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Concurrent Lymphoid Malignancy

Zachary Zimmerman, MD, PhD, Bart L. Scott, MD, Ajay K. Gopal, MD, Brenda M. Sandmaier, MD, David G. Maloney, MD, PhD, and H. Joachim Deeg, MD
Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, WA

Abstract

Allogeneic hematopoietic cell transplantation (HCT) can be curative for both myelodysplastic syndromes (MDS) and lymphoid malignancies. Little is known about the efficacy of allogeneic HCT in patients in whom both myeloid and lymphoid disorders are present at the time of HCT. We analyzed outcomes in 21 patients with MDS and concurrent lymphoid malignancy when undergoing allogeneic HCT. Seventeen patients had received extensive prior cytotoxic chemotherapy, including autologous HCT in seven, for non-Hodgkin lymphoma (NHL, n=7), Hodgkin lymphoma (HL, n=2), chronic lymphocytic leukemia (CLL, n=5), NHL plus HL (n=1), multiple myeloma (n=1), or T-cell acute lymphocytic leukemia (ALL) (n=1), and had, presumably, developed MDS as a consequence of therapy. Four previously untreated patients had CLL. Nineteen patients were conditioned with high-dose (n=14) or reduced-intensity regimens (n=5), and transplanted from HLA-matched or one antigen/allele mismatched related (n=10) or unrelated (n=9) donors; two patients received HLA-haplodienstic related transplants following conditioning with a modified conditioning regimen. Currently, 2 of 4 previously untreated, and 2 of 17 previously treated patients are surviving in remission of both MDS and lymphoid malignancies. However, the high non-relapse mortality among previously treated patients, even with reduced-intensity conditioning regimens, indicates that new transplant strategies need to be developed.

Keywords
concurrent MDS and lymphoid malignancy; conditioning regimens; secondary MDS; relapse

CONFLICT OF INTEREST
The authors declare no conflict of interest.
INTRODUCTION

Myelodysplastic syndrome (MDS) is a well described complication of cytotoxic chemotherapy as treatment for lymphoid malignancies.\textsuperscript{1–4} It may occur after non-transplant cytotoxic therapy or after autologous hematopoietic cell transplantation (HCT). In fact, published data suggest that MDS after autologous HCT is related to pre-HCT therapy.\textsuperscript{1,5} Occasionally, however, MDS is diagnosed in previously untreated patients simultaneously with lymphoma.\textsuperscript{6–9} Allogeneic HCT offers potentially curative treatment for both disease entities, including patients who have failed to respond to non-transplant therapy.\textsuperscript{10,11} We and others have previously reported experience with allogeneic HCT for patients with therapy-related MDS following treatment for lymphoid malignancies, but without evidence of the primary disease at the time of HCT.\textsuperscript{12,13} In the present study, we identified patients who underwent allogeneic HCT for MDS, but concurrently had an active lymphoid malignancy, either diagnosed simultaneously with MDS or preceding the diagnosis of MDS. Patients with antecedent lymphoid malignancies had received cytotoxic therapy. Patients included in this report were treated over an extended time interval during which treatment strategies have evolved. However, the data should draw attention to this patient population for which more effective therapeutic options must be developed.

PATIENTS AND METHODS

From a database of 1100 patients with MDS or related disorders who underwent allogeneic HCT at the Fred Hutchinson Cancer Research Center (FHCRC) from 1990 through 2009, 21 patients were identified who, in addition to MDS, had an active lymphoid malignancy present at the time of HCT. The study was approved by the Institutional Review Board of the FHCRC.

Patients without prior cytotoxic therapy

Four patients had never received cytotoxic chemotherapy, and MDS appeared to represent a \textit{de novo} disorder (Cohort A, Table 1). These patients ranged in age from 41 to 65 (median 57) years at the time of HCT. The MDS subtypes according to WHO Classification are shown in Table 1. Median percentage of marrow myeloblasts was 9.3\%. Two of the four patients had good-risk cytogenetics (normal karyotype) , and two had an intermediate-risk karyotype by International Prognostic Scoring System (IPSS) criteria.\textsuperscript{14} The IPSS scores ranged from 0.5 to 2.0 with a median score of 0.5. All four patients were diagnosed concurrently to also have chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL), stage 0. All patients received high-dose conditioning followed by hematopoietic stem cell infusion from HLA-matched related or unrelated donors. Further details are provided in Table 1.

Patients who had received prior cytotoxic therapy

Seventeen patients, 29–71 (median 50.4) years of age, had previously received cytotoxic therapy (Cohort B, Table 1). Among these, seven had undergone high-dose chemotherapy followed by autologous HCT. Details are provided in Table 1. In addition to MDS, five patients had concurrent CLL, while the remainder had other lymphoid malignancies.
including follicular lymphoma, diffuse large B cell (DLBCL) Non-Hodgkin lymphoma (NHL), HL, or multiple myeloma. One patient had T-cell ALL. Five patients had good-risk, one intermediate-risk, and 11 high-risk/complex karyotypes. The median marrow myeloblast percentage was 11.3%. In 14 of 17 patients there was marrow involvement by the lymphoid malignancy. Supradiaphragmatic or infradiaphragmatic lymph node enlargement was present in both patients with HL, in 5 of 7 patients with NHL, and in the patient with HL and DLBCL. CLL was Rai stage 0 in one patient, stage I in 1 patient, and stage IV in the remaining 3 patients. The patient with myeloma was staged as Durie-Salmon stage I. Ten patients were conditioned with high-dose regimens, while five patients received low-intensity conditioning regimens. The remaining two patients were transplanted with marrow from haploidentical children following conditioning with a modified reduced-intensity regimen (see Table 1).

**Source of stem cells**

The stem cell source was bone marrow in one of four patients with primary MDS, while three patients were given G-CSF mobilized peripheral blood stem cells (PBSC). In patients with secondary MDS, nine received marrow and eight received G-CSF mobilized PBSC as a source of stem cells.

**Conditioning regimens**

Conditioning regimens varied and were dependent upon patient age, comorbidity, disease stage, donor availability, and the type of research protocol active at the Center at the time of the patients’ HCT. Four patients were conditioned with fludarabine (Flu) at 30 mg/m^2/day i.v. for 3 consecutive days and 2 Gy of total body irradiation (TBI). Three patients received Flu, 30 mg/m^2/day for 5 days, plus cyclophosphamide (Cy) 2×14.5 mg/kg i.v., and 2 Gy TBI. Three patients received Cy, 60 mg/kg i.v., for 2 consecutive days and 6×2 Gy of TBI over three 3 days. Four patients received busulfan (Bu), prescribed dose 16 mg/kg p.o., over 4 days (with dose adjustments to achieve steady state plasma levels of 800–900 ng/mL [targeted Bu]) plus Cy, 60 mg/kg i.v., for two 2 consecutive days. The remaining patients received Flu, 40 mg/m^2/day i.v., for 3 days, and targeted Bu starting with a prescribed dose of 16 mg/kg; Flu, 40 mg/m^2/day i.v., for 5 days, and targeted Bu with anti-thymocyte globulin (ATG; Atgam); or targeted Bu over 4 days plus Cy, 60 mg/kg/day i.v., for 2 days plus ATG.15

**GVHD prophylaxis and therapy**—Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine (CSP) and methotrexate (MTX) in 12 patients, tacrolimus18 and MTX in 4, CSP and mycophenolate mofetil (MMF) in 4, tacrolimus and MMF in 1, and CSP alone in 1 patient. The diagnosis of acute and chronic GVHD were made by established criteria.19,20

**Assessment of results**

Engraftment, GVHD and relapse were assessed as previously described.15,21,22 Patients who died with evidence of persistent or recurrent disease – MDS or lymphoid malignancy – were considered to have died from MDS/lymphoid malignancy, regardless of the immediate cause of death. All other deaths were considered to be related to non-relapse causes.
Data were analyzed as of July 19, 2010.

RESULTS

Engraftment

All patients with primary MDS (Table 2) achieved neutrophil engraftment (>0.5 × 10^9 /L for three days) by day 28. Among patients with secondary MDS, 15 patients achieved neutrophil engraftment; two patients died early (at 14 and 7 days, respectively) from non-relapse causes and, thus, were not evaluable for engraftment (Table 2). All remaining patients had achieved engraftment by day 44.

GVHD—Among patients with primary MDS (Cohort A), two (50%) developed acute GVHD grades I–II, and two developed chronic GVHD. Among patients with secondary MDS (Cohort B), 13 of 15 evaluable patients (87%) developed acute GVHD, grades I–II in 10, and grades III–IV in 3 patients, and 7 of 13 patients at risk developed chronic GVHD (Table 2).

Relapse—Among four patients with primary MDS, two (50%) showed persistence of CLL and eventually relapsed with MDS. Among 17 patients with secondary MDS one (patient 7) died too early to assess for clearance of the disease. Among the remaining 16 patients, the lymphoid malignancy persisted in three (patients 9, 10 and 15), which was not unexpected as clonal cells in these disorders often clear only gradually. However, two patients (patients 9 and 15) died with progression of their lymphoid malignancy and associated complications, while one patient (patient 10) died with relapsed MDS. In the remaining 13 patients, both myeloid and lymphoid malignancies cleared after HCT before relapse was documented in four of them (Table 2).

Survival—The median follow-up for all patients was 6.2 months. At the time of analysis, 2 of 4 patients with primary MDS were alive without evidence of disease at 14 and 4 years after HCT, respectively. Two patients had died with relapse of MDS and CLL at 5.1 and 46 months, respectively (Table 2).

Among patients with secondary MDS, 2 of 17 patients were alive at the time of analysis, in apparent remission of MDS and lymphoid malignancy, at 11.9 and 15 years after HCT, respectively. Nine patients died from non-relapse causes, and six from disease relapse. For all 17 patients the median relapse-free survival was 4.3 months, and the median overall survival was 6.2 months (Table 2).

DISCUSSION

We identified 21 patients who underwent allogeneic HCT for MDS in the setting of a concurrent lymphoid malignancy. In four patients the concurrent diagnoses of MDS and lymphoid malignancy were established simultaneously prior to any therapy. Seventeen patients received a diagnosis of MDS following a preceding diagnosis of and therapy for their lymphoid malignancy and, therefore, were considered to have secondary MDS. Our findings are consistent with previous studies, which have shown the presence of various
lymphoid malignancies in association with MDS.\textsuperscript{6} Also consistent with previous reports is the fact that the most frequent lymphoid malignancy among patients with MDS was CLL.\textsuperscript{6}

The relationship between primary MDS and lymphoid malignancies is unclear. While MDS is considered a myeloid disorder, it can, rarely, transform to acute lymphocytic leukemia.\textsuperscript{24} Furthermore, in an experimental xenotransplantation model of MDS, identical clonal abnormalities have been demonstrated in lymphoid and myeloid precursors.\textsuperscript{25} Consistent with such a model, MDS-associated cytogenetic abnormalities have been observed in circulating lymphoid cells in MDS patients.\textsuperscript{26} However, in the majority of reports of lymphoid malignancies associated with MDS, there has been no evidence of a common cell of origin.\textsuperscript{7–9,27} As both disorders occur with increasing frequency at older age, the simultaneous diagnosis of two malignancies may be a coincidence. By the age of 60 years about 3\% of the population express small B cell clones, and progression to CLL has been observed.\textsuperscript{28,29} It is conceivable that immunological abnormalities associated with MDS may facilitate such a progression.\textsuperscript{30,31}

The development of MDS following treatment for other malignancies, including lymphoid neoplasms is well documented.\textsuperscript{1,2,32} As observed here, those patients typically show higher risk features, in particular high -risk cytogenetics, than do patients with de novo MDS.\textsuperscript{1} The 17 patients considered here had received cytotoxic chemotherapy, but showed persistent or recurrent evidence of their lymphoid malignancies at the time of HCT for MDS. Thus, the transplant was undertaken in an attempt to eradicate both MDS and lymphoid malignancy. Treatment failures among patients with de novo MDS were related to relapse of either MDS or CLL. Among patients with secondary MDS, relapses of either myeloid or lymphoid malignancy (or both) occurred in seven patients, but mortality was due primarily to non-relapse causes. The most prominent causes of death were related to infections. As all these patients had previously received cytotoxic chemotherapy, often with multiple agents and for multiple cycles, increased non-relapse mortality was expected.

It was of note in the cohort with secondary MDS, that patients experienced relapse of one, but not the other disease, suggesting that a given conditioning regimen was effective in eradicating myeloid or lymphoid malignant cells, but not both. However, these data should be interpreted with great caution as the tumor burden of the two malignancies may have differed significantly. Also, the follow-up for some of these patients was short.

Of the five patients conditioned with low -intensity conditioning regimens, three died from non-relapse causes as did 6 of 10 patients conditioned with higher -intensity regimens. Both patients who underwent haploidentical transplants died from relapse. Nevertheless, two patients with de novo MDS and CLL (one transplanted from a related and one from an unrelated donor) are surviving in remission from both diseases, as are two patients with secondary MDS, whose original lymphoid malignancies were HL and NHL, respectively.

Taken together, these data suggest that patients with MDS and concurrent lymphoid malignancies, diagnosed simultaneously or metachronously, should not,\textit{a priori} be excluded from consideration of transplantation. However, both relapse and non-relapse mortality were high, and better tolerable regimens must be developed, particularly for patients with
secondary MDS. As therapy given for the initial diagnosis of a lymphoid malignancy may vary greatly, "custom-designed" conditioning regimens should aim at minimizing toxicity that may develop on the background of previously administered therapy. Conceivably, post-HCT adjuvant therapy, for example with hypomethylating agents,\(^3\) directed at MDS or with rituximab directed at certain lymphoid malignancies, might reduce the relapse risk without adding to transplant-related toxicity.

**Acknowledgments**

We thank all patients for consenting to these studies, the physicians and nurses caring for the patients, Franchesca Nguyen for maintaining the database, and Helen Crawford and Bonnie Larson for help with manuscript preparation.

The authors are grateful for research funding from the National Institutes of Health, Bethesda, MD grants P01HL036444, P01CA078902, P01CA018029, and K23HL084054. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health nor its subsidiary Institutes and Centers.

Ajay K. Gopal is a scholar in clinical research of the Leukemia and Lymphoma Society.

**References**

1. Metayer C, Curtis RE, Vose J, Sobocinski KA, Horowitz MM, Bhatia S, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood. 2003; 101:2015–2023. [PubMed: 12393427]
2. De Roos AJ, Deeg HJ, Scott D. A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers. Cancer Causes Control. 2007; 18:1199–1208. [PubMed: 17823848]
3. Rosenbloom B, Schreck R, Koeffler HP. Therapy-related myelodysplastic syndromes (Review). Hematology - Oncology Clinics of North America. 1992; 6:707–722.
4. André M, Mounier N, Leleu X, Sonet A, Brice P, Henry-Amar M, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood. 2004; 103:1222–1228. [PubMed: 14576060]
5. Govindarajan R, Jagannath S, Flick JT, Vesole DH, Sawyer J, Barlogie B, et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol. 1996; 95:349–353. [PubMed: 8904891]
6. Florena L, Vallespi T, Woessner S, Domingo A, Crespo N, Rozman M, et al. Incidence and characteristics of lymphoid malignancies in untreated myelodysplastic syndromes. Leuk Lymphoma. 1996; 23:609–612. [PubMed: 9031093]
7. Mossafa H, Fourcade C, Punic M, Jury L, Cheze S, Szpiro-Tapia S, et al. Chronic lymphocytic leukemia associated with myelodysplastic syndrome and/or chronic myeloid leukemia: evidence for independent clonal chromosomal evolution. Leuk Lymphoma. 2001; 41 :337–341. [PubMed: 11378546]
8. Sylvester LS, Nowell PC, Bonner H, Moreau L, Moore JS. Concurrent diagnosis of chronic lymphocytic leukemia and myelodysplastic syndrome. Leuk Res. 1997; 21:619–621. [PubMed: 9301682]
9. Aviv H, Tang D, Das K, Harrison JS, Hameed M, Varma M. Simultaneous appearance of trisomy 8 and trisomy 12 in different cell populations in a patient with untreated B-cell chronic lymphocytic leukemia and myelodysplasia. Leuk Lymphoma. 2004; 45:1279–1283. [PubMed: 15360013]
10. Parmar S, de Lima M. Hematopoietic stem cell transplantation for myelodysplastic syndrome (Review). Biol Blood Marrow Transplant. 2010; 16:S37–S44. [PubMed: 1985789]
11. Wrench D, Gribben JG. Stem cell transplantation for non-Hodgkin’s lymphoma (Review). Hematology - Oncology Clinics of North America. 2008; 22:1051–1079.
12. Litzow MR, Tarima S, Perez WS, Bolwell BJ, Cairo MS, Camitta BM, et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood. 2010; 115:1850–1857. [PubMed: 20032503]

13. Chang CK, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME, et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood. 2007; 110:1379–1387. [PubMed: 17488876]

14. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes [erratum appears in Blood 1998 Feb 1;91(3):1100]. Blood. 1997; 89:2079–2088. [PubMed: 9058730]

15. Deeg HJ, Storb R, Boeckh M, Martin PJ, McCune JS, Myerson D, et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant. 2006; 12:573–584. [PubMed: 16635793]

16. Deeg HJ, Storb R, Thomas ED, Flourny N, Kennedy MS, Banaji M, et al. Cyclosporine as prophylaxis for graft-versus-host disease: A randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood. 1985; 65:1325–1334. [PubMed: 388312]

17. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986; 314:729–735. [PubMed: 7510076]

18. Nash RA, Etzioni R, Storb R, Furlong T, Gooley T, Anasetti C, et al. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: A single-center study. Blood. 1995; 85:3746–3753. [PubMed: 7540071]

19. Przepiorka D, Weisdorf D, Martin P, Klingemann H-G, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995; 15:825–828. [PubMed: 7581076]

20. Lee SJ, Vogelsang G, Flowers MED. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003; 9:215–233. [PubMed: 12720215]

21. Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG, et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia. 2006; 20:128–135. [PubMed: 16270037]

22. Petersdorf EW, Longton GM, Anasetti C, Mickelson EM, McKinney SK, Smith AG, et al. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood. 1997; 89:1818–1823. [PubMed: 9057668]

23. Sorror ML, Storer BE, Sandmaier BM, Maris M, Shizuru J, Maziarcz R, et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol. 2008; 26:4912–4920. [PubMed: 18794548]

24. Sato N, Nakazato T, Kizaki M, Ikeda Y, Okamoto S. Transformation of myelodysplastic syndrome to acute lymphoblastic leukemia: a case report and review of the literature (Review). Int J Hematol. 2004; 79:147–151. [PubMed: 15005342]

25. Thanopoulou E, Cashman J, Kakagianne T, Eaves A, Zoumbos N, Eaves C. Engraftment of NOD/SCID-β2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome. Blood. 2004; 103:4285–4293. [PubMed: 14962905]

26. White NJ, Nacheva E, Asumakopoulous FA, Bloxham D, Paul B, Green AR. Deletion of chromosome 20q in myelodysplasia can occur in a multipotent precursor of both myeloid cells and B cells. Blood. 1994; 83:2809–2816. [PubMed: 8180377]

27. Mitterbauer G, Schwarzmeier J, Mitterbauer M, Jaeger U, Fritsch G, Schwarzinger I. Myelodysplastic syndrome/acute myeloid leukemia supervening previously untreated chronic B-lymphocytic leukemia: demonstration of the concomitant presence of two different malignant
clones by immunologic and molecular analysis. Ann Hematol. 1997; 74:193–197. [PubMed: 9174549]

28. Rawstron AC, Bennett FL, O’Connor SJ, Kwok M, Fenton JA, Plummer M, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med. 2008; 359:575–583. [PubMed: 18687638]

29. Landgren O, Albitar M, Ma W, Abbasi F, Hayes RB, Ghia P, et al. B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med. 2009; 360:659–667. [PubMed: 19213679]

30. Campregher PV, Srivastava SK, Deeg HJ, Robins HS, Warren EH. Abnormalities of the αβ T-cell receptor repertoire in advance myelodysplastic syndrome. Exp Hematol. 2010; 38 :202–212. [PubMed: 20035823]

31. Fozza C, Contini S, Galleu A, Simula MP, Virdis P, Bonfigli S, et al. Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset. Exp Hematol. 2009; 37:947–955. [PubMed: 19409953]

32. Leone G, Pagano L, Ben Yehuda D, Voso MT. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica. 2007; 92:1389–1398. [PubMed: 17768113]

33. de Lima M, Giralt S, Thall PF, De Padua SL, Jones RB, Komanduri K, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010; 116:5420–5431. [PubMed: 20672358]
# Demographic and transplant characteristics

| Patient No. | MDS Subtype | Marrow Blast (%) | IPSS | Karyotype | Lymphoid Malignancy | Age at Tx (years) | Donor / Cell Source | Conditioning | GVHD prophylaxis |
|-------------|-------------|------------------|------|-----------|--------------------|------------------|---------------------|--------------|-----------------|
| Cohort A: No prior cytotoxic therapy |
| 1 | RA | 4 | 0.5 | 46 XY | CLL | 65 | MRD / BM | Cy 120mg/kg / TBI 10 Gy | CSP / MTX |
| 2 | RAEB | 6 | 0.5 | 46XY | CLL | 63 | MRD / PBSC | Flu 3x40 mg/m² / tBu | CSP / MTX |
| 3 | ET/MF/MDS | 1 | N/A | 48,XY,+8,+9 | CLL | 61 | MRD / PBSC | Flu 5x40 mg/m² / tBu / ATG | FK / MTX |
| 4 | RAEB | 18 | 2 | 46,XX,add(2)(q37) | CLL | 41 | URD / PBSC | tBu / Cy 120mg/kg | FK / MTX |
| Cohort B: Prior cytotoxic therapy |
| 5 | RA | <1 | 0 | 46XY | CLL | 49 | URD / BM | Cy 120 mg/kg / TBI 6x2 Gy | CSP / MTX |
| 6 | RAEB/AML | 50 | 2.5 | 46XY | MM | 52 | URD / BM | Cy 120 mg/kg / TBI 6x2 Gy | CSP / MTX |
| 7 | RAEB | 7 | 3 | Complex | HL | 47 | MRD / BM | Cy 120 mg/kg / tBu | CSP / MTX |
| 8 | RA/AML | 31 | N/A | Complex | HL | 41 | URD / BM | Cy 120 mg/kg / TBI 6x2 Gy | CSP / MTX |
| 9 | RA | <1 | 0.5 | 46xy | CLL | 52 | MRD / PBSC | Cy 120 mg/kg / tBu | CSP / MTX |
| 10 | RARS | <1 | 0.5 | Complex | CLL | 64 | MRD / PBSC | Flu 90 mg/m² / TBI 2 Gy | FK / MMF |
| 11 | RA | 4 | 0 | 46,XY,del(20)(q11.2q13.3) | FL (grade III) | 50 | MMURD / PBSC | Cy 120 mg/kg / TBI 6x2 Gy | FK / MTX |
| 12 | RA | 4 | 0.5 | 47,XY,+8 | HL + DLBCL | 49 | MRD / BM | Cy 120 mg/kg / TBI 6x2 Gy | CSP / MTX |
| 13 | CMML | 21 | 2.5 | 46,XY,del(20)(q11.2q13.3) | CLL | 51 | URD / PBSC | Cy 120 mg/kg / tBu / ATG | CSP / MTX |
| 14 | RA | 4 | 1.5 | Complex | CLL | 50 | URD / BM | Cy 120 mg/kg / tBu | CSP / MTX |
| 15 | RA | <1 | 1 | Complex | FL | 55 | MRD / PBSC | Flu 90 mg/m² / TBI 2 Gy | CSP / MMF |
| Patient No. | MDS Subtype | Marrow Blast (%) | IPSS | Karyotype | Lymphoid Malignancy | Age at Tx (years) | Donor / Cell Source | Conditioning | GVHD prophylaxis |
|------------|-------------|-----------------|------|-----------|---------------------|------------------|-------------------|--------------|-----------------|
| 16         | RA          | <1              | 1    | Complex   | DLBCL               | 29               | URD / BM          | Cy 120 mg/kg / Bu | CSP / MTX   |
| 17         | RAEB        | 13              | 2.5  | Complex   | T-ALL               | 37               | Haploidentical sibling / BM | Flu 30 mg/m² / Cy 14.5 / mg/kg⁴ / TBI 2 Gy | FK / MMF |
| 18         | RA          | 2               | 1.5  | Complex   | FL                  | 51               | MRD / PBSC        | Flu 90 mg/m² / TBI 2 Gy | CSP / MMF |
| 19         | RA          | 5               | 1    | Complex   | FL                  | 52               | URD / PBSC        | Flu 90 mg/m² / TBI 2 Gy | CSP / MMF |
| 20         | RA          | 4               | 1    | Complex   | DLBCL               | 57               | MMURD⁴ / PBSC     | Flu 150 mg/m² / TBI 2 Gy | FK / MTX |
| 21         | RA          | 4               | 1    | Complex   | DLBCL               | 71               | Haploidentical sibling / BM | Flu 150 mg/m² / Cy 29 mg/kg⁴ / TBI 2 Gy | FK / MMF |

Patients 15–21 had previously received autologous HCT.

ₐ The intensity of cytotoxicity and the numbers of cycles given varied widely.

₉ A antigen, B allele mismatched.

⁵ B allele mismatched.

₄ Patients also received Cy, 50 mg/kg, on day 3 after transplantation.

Abbreviations: AML= acute myeloid leukemia arising from MDS; ATG= antithymocyte globulin; BM= bone marrow; Bu= busulfan; CLL= chronic lymphocytic leukemia; CMML= chronic myelomonocytic leukemia; CSP / MTX= cyclosporine + methotrexate; Cy= cyclophosphamide; DLBCL= diffuse large B-cell lymphoma; ET/MF/MDS= Essential thrombocythemia evolving to myelofibrosis and transforming to myelodysplastic syndrome; FK= tacrolimus; FL= follicular lymphoma; Fl= fludarabine; GVHD= graft-versus-host disease; HL= Hodgkin lymphoma; IPSS= International Prognostic Scoring System; MDS= myelodysplastic syndrome; MM= multiple myeloma; MMF= mycophenolate mofetil; MMURD= HLA-mismatched URD; MRD= HLA-matched related donor; N/A= not applicable; PBSC= G-CSF mobilized peripheral blood progenitor cells; RA= refractory anemia; RAEB= refractory anemia with excess blasts; RARS= RA with ring siderblasts; T-ALL= T-cell acute lymphoblastic leukemia; TBI= total body irradiation; Bu= busulfan starting at 1 mg/kg every 6 hours, for 16 doses, with dose adjustment to achieve pre-determined trough levels at doses 5, 9, and 13; Tx= transplantation; URD= HLA-matched unrelated donor.
| Patient No. | Grade (skin) | Acute GvHD/grade/organ(s) involved | Chronic GVHD | Relapse | Outcome / COD | RFS (ms) | OS (ms) |
|-------------|-------------|-----------------------------------|--------------|---------|----------------|---------|---------|
| Cohort A    |             | 1                                 |              |         | Alive          | 268.3   | >170.3  |
|             | Yes         | No                                | N/A          | No      | Relapse        |         |         |
|             | No          | Relapse                           | Persistent CLL| No      | No             | 4.5     | 5.17    |
|             | No          | Relapse                           | Persistent CLL| No      | No             |         |         |
|             | No          | Relapse                           | Persistent CLL| No      | No             | 0.5     |         |
|             | No          | Relapse                           | Persistent CLL| No      | No             | 0.5     |         |
|             | No          | Relapse                           | Persistent CLL| No      | No             | 0.5     |         |
|             | No          | Relapse                           | Persistent CLL| No      | No             | 0.5     |         |
|             | No          | Relapse                           | Persistent CCL / Relapse MDS | No | No | 2.8  | 4.0 |
|             | No          | Relapse                           | Persistent CCL / Relapse MDS | No | No | 4.5  | 4.5 |
|             | No          | Relapse                           | Persistent CCL / Relapse MDS | No | No | 1.0  | 6.2 |
|             | No          | Relapse                           | Persistent CCL / Relapse MDS | No | No | 3.7  | 3.7 |
|             | No          | Relapse                           | Persistent CCL / Relapse MDS | No | No | 104.4 | 178.4 |
|             | No          | Relapse                           | Persistent CCL / Relapse MDS | No | No | 1.0  | 4.3 |
|             | No          | Relapse                           | Persistent CCL / Relapse MDS | No | No | 0.3  | 0.3 |
|             | No          | Relapse                           | Persistent CCL / Relapse MDS | No | No | 25.8 | 25.8 |
|             | No          | Relapse                           | Persistent CCL / Relapse MDS | No | No | 31.2 | 31.2 |
|             | No          | Relapse                           | Persistent CCL / Relapse MDS | No | No | 2.9  | 8.4 |

Bone Marrow Transplant. Author manuscript; available in PMC 2012 December 01.
